

# MICTONORM®

## PROPIVERINE FOR URINARY INCONTINENCE

Another anticholinergic, no more.



IMPORTANT THERAPEUTIC INNOVATION



MODEST THERAPEUTIC INNOVATION



SOME ADDED VALUE IN SPECIFIC SITUATIONS



**NO THERAPEUTIC INNOVATION**



INSUFFICIENT EVIDENCE

+  
DATA SHEET

### WHAT IS IT?

Urinary antispasmodic with antimuscarinic properties.

### INDICATION

Symptomatic treatment of urinary incontinence and / or increased urinary frequency and urgency in patients with overactive bladder syndrome.

### POSOLOGY AND METHOD OF ADMINISTRATION

One capsule (30 mg) once a day, with or without food. It is recommended to reevaluate the effectiveness after 4 weeks of treatment.

### EFFECTIVENESS

Compared to tolterodine 4 mg: There are no differences in effectiveness in reducing the number of episodes of urination in 24 hours. No inferiority.

### RISKS

**Anticholinergic effects:** dry mouth, headache, accommodation disturbances, visual impairment, constipation, abdominal pain, dyspepsia and fatigue.

**Liver function:** reversible alterations of liver enzymes may occur, so they should be monitored in long-term treatments. It is not recommended in patients with moderate to severe hepatic impairment.

**Caution:** in patients with autonomic neuropathy, severe congestive heart failure, prostatic hypertrophy, hiatus hernia with esophageal reflux, arrhythmias and angle-closure glaucoma. In the elderly, risk of cognitive impairment.

### PLACE IN THERAPEUTICS

Efficacy and safety similar to tolterodine. Like other drugs of the same class, it would only be indicated when the non-pharmacological measures are insufficient.

### PRESENTATIONS

Mictonorm® 30 mg, 28 capsules of modified release (30.91 €).

Low efficacy that hardly compensates for adverse effects.



REPORT [IN SPANISH]

### DAILY COST TREATMENT (€)

TOLTERODINE 4 MG 1.02

PROPIVERINE 30 MG 1.10

0 0.2 0.4 0.6 0.8 1 1.2